23:32 , Jun 24, 2019 |  BC Extra  |  Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
23:43 , Jun 17, 2019 |  BC Extra  |  Company News

BeiGene exploring commercialization options for returned PD-1 inhibitor

After regaining global rights to PD-1 inhibitor tislelizumab from Celgene, BeiGene is exploring options to commercialize the asset on its own or find a partner for the product in the U.S., Europe and Japan. The...
22:06 , May 7, 2019 |  BC Extra  |  Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU  The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
01:31 , Mar 15, 2019 |  BC Innovations  |  Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
19:59 , Nov 16, 2018 |  BioCentury  |  Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of BioCentury Innovations , a comprehensive source of developments in translational research with knowledgeable perspectives on the key innovations, trends and opportunities in...
22:43 , Nov 15, 2018 |  BC Innovations  |  Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade...
23:56 , Sep 28, 2018 |  BioCentury  |  Finance

Paper chase

Even before this week’s spate of IPOs, this year’s class of newly public biotechs on NASDAQ had surpassed that of 2017 in terms of funds raised, leaving this year’s class within striking distance of 2015’s...
18:19 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Sutro raises about $95M total in IPO, private placement

Sutro Biopharma Inc. (NASDAQ:STRO) raised $85 million late Sept. 26 through the sale of 5.7 million shares at $15 in an upsized IPO underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. The price,...
04:53 , Sep 28, 2018 |  BC Extra  |  Financial News

Gritstone dips after $100M IPO

Adding to the flurry of life sciences IPOs this week, Gritstone Oncology Inc. (NASDAQ:GRTS) raised $100 million through the sale of 6.7 million shares at $15 in its IPO late Thursday. The price was at...